{"id":27497,"date":"2023-07-20T15:20:27","date_gmt":"2023-07-20T19:20:27","guid":{"rendered":"https:\/\/marymount.edu\/academics\/?p=27497"},"modified":"2023-07-20T15:20:27","modified_gmt":"2023-07-20T19:20:27","slug":"lecanemab-frequently-asked-questions","status":"publish","type":"post","link":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/","title":{"rendered":"Lecanemab Frequently Asked Questions"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

Introducing “Lecanemab Frequently Asked Questions<\/strong>“: On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and Biogen, for the treatment of early-stage Alzheimer’s disease. Lecanemab, administered through intravenous infusion every two weeks, is a monoclonal antibody designed to bind and remove amyloid plaques in the brain, which are associated with Alzheimer’s disease. While it does not provide a cure, lecanemab has demonstrated the potential to slow the progression of the disease, with a 27% reduction in cognitive decline observed in clinical trials. This FAQ document addresses various questions about lecanemab, including its administration, safety, candidacy requirements, availability, and associated costs. Please note that additional steps are required before the medication becomes available, and Medicare coverage is subject to certain conditions and costs.<\/p>\n

Click Here<\/a> to read the full FAQ document.<\/p>\n

 <\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n

 <\/p>\n

<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Introducing “Lecanemab Frequently Asked Questions“: On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and Biogen, for the treatment of early-stage Alzheimer’s disease. Lecanemab, administered through intravenous infusion every two weeks, is a monoclonal antibody designed to bind and remove amyloid plaques in the brain, which are associated […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":172,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_lmt_disableupdate":"no","_lmt_disable":"no","ngg_post_thumbnail":0,"footnotes":""},"categories":[74],"tags":[],"class_list":["post-27497","post","type-post","status-publish","format-standard","hentry","category-mcoa-in-the-news"],"acf":[],"yoast_head":"\nLecanemab Frequently Asked Questions - Marymount University<\/title>\n<meta name=\"description\" content=\"Introducing "Lecanemab Frequently Asked Questions": On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lecanemab Frequently Asked Questions\" \/>\n<meta property=\"og:description\" content=\"Introducing "Lecanemab Frequently Asked Questions": On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/\" \/>\n<meta property=\"og:site_name\" content=\"Academics - Marymount University\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-20T19:20:27+00:00\" \/>\n<meta name=\"author\" content=\"ybt68349\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@marymountuser\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ybt68349\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/\"},\"author\":{\"name\":\"ybt68349\",\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/#\\\/schema\\\/person\\\/4669f0696c142a25afd429226632b32d\"},\"headline\":\"Lecanemab Frequently Asked Questions\",\"datePublished\":\"2023-07-20T19:20:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/\"},\"wordCount\":139,\"articleSection\":[\"MCOA in the News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/\",\"url\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/\",\"name\":\"Lecanemab Frequently Asked Questions - Marymount University\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/#website\"},\"datePublished\":\"2023-07-20T19:20:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/#\\\/schema\\\/person\\\/4669f0696c142a25afd429226632b32d\"},\"description\":\"Introducing \\\"Lecanemab Frequently Asked Questions\\\": On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/lecanemab-frequently-asked-questions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Academics\",\"item\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lecanemab Frequently Asked Questions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/#website\",\"url\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/\",\"name\":\"Academics - Marymount University\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/#\\\/schema\\\/person\\\/4669f0696c142a25afd429226632b32d\",\"name\":\"ybt68349\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/af2889924b6efd724495b39d160e8ff106fce69a0695f643ebf807755b8237db?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/af2889924b6efd724495b39d160e8ff106fce69a0695f643ebf807755b8237db?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/af2889924b6efd724495b39d160e8ff106fce69a0695f643ebf807755b8237db?s=96&d=mm&r=g\",\"caption\":\"ybt68349\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/marymountuser\"],\"url\":\"https:\\\/\\\/marymount.edu\\\/academics\\\/author\\\/ybt68349\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lecanemab Frequently Asked Questions - Marymount University","description":"Introducing \"Lecanemab Frequently Asked Questions\": On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/","og_locale":"en_US","og_type":"article","og_title":"Lecanemab Frequently Asked Questions","og_description":"Introducing \"Lecanemab Frequently Asked Questions\": On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and","og_url":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/","og_site_name":"Academics - Marymount University","article_published_time":"2023-07-20T19:20:27+00:00","author":"ybt68349","twitter_card":"summary_large_image","twitter_creator":"@marymountuser","twitter_misc":{"Written by":"ybt68349","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/#article","isPartOf":{"@id":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/"},"author":{"name":"ybt68349","@id":"https:\/\/marymount.edu\/academics\/#\/schema\/person\/4669f0696c142a25afd429226632b32d"},"headline":"Lecanemab Frequently Asked Questions","datePublished":"2023-07-20T19:20:27+00:00","mainEntityOfPage":{"@id":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/"},"wordCount":139,"articleSection":["MCOA in the News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/","url":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/","name":"Lecanemab Frequently Asked Questions - Marymount University","isPartOf":{"@id":"https:\/\/marymount.edu\/academics\/#website"},"datePublished":"2023-07-20T19:20:27+00:00","author":{"@id":"https:\/\/marymount.edu\/academics\/#\/schema\/person\/4669f0696c142a25afd429226632b32d"},"description":"Introducing \"Lecanemab Frequently Asked Questions\": On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and","breadcrumb":{"@id":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marymount.edu\/academics\/lecanemab-frequently-asked-questions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Academics","item":"https:\/\/marymount.edu\/academics\/"},{"@type":"ListItem","position":2,"name":"Lecanemab Frequently Asked Questions"}]},{"@type":"WebSite","@id":"https:\/\/marymount.edu\/academics\/#website","url":"https:\/\/marymount.edu\/academics\/","name":"Academics - Marymount University","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marymount.edu\/academics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/marymount.edu\/academics\/#\/schema\/person\/4669f0696c142a25afd429226632b32d","name":"ybt68349","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/af2889924b6efd724495b39d160e8ff106fce69a0695f643ebf807755b8237db?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/af2889924b6efd724495b39d160e8ff106fce69a0695f643ebf807755b8237db?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/af2889924b6efd724495b39d160e8ff106fce69a0695f643ebf807755b8237db?s=96&d=mm&r=g","caption":"ybt68349"},"sameAs":["https:\/\/x.com\/marymountuser"],"url":"https:\/\/marymount.edu\/academics\/author\/ybt68349\/"}]}},"modified_by":"ybt68349","_links":{"self":[{"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/posts\/27497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/users\/172"}],"replies":[{"embeddable":true,"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/comments?post=27497"}],"version-history":[{"count":2,"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/posts\/27497\/revisions"}],"predecessor-version":[{"id":27500,"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/posts\/27497\/revisions\/27500"}],"wp:attachment":[{"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/media?parent=27497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/categories?post=27497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marymount.edu\/academics\/wp-json\/wp\/v2\/tags?post=27497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}